Sama Therapeutics and Quine Biologics Announce Collaboration to Develop Breakthrough Antibody Therapeutics for Neurological Disorders

Sama Therapeutics and Quine Biologics Announce Collaboration to Develop Breakthrough Antibody Therapeutics for Neurological Disorders

Sama Therapeutics and Quine Biologics have partnered to develop an innovative therapy for neurological disorders, combining AI-driven platforms and advanced antibody engineering. The collaboration focuses on biologics that precisely target the central nervous system, minimizing side effects. By integrating Sama's generative AI with Quine's antibody design expertise, the project addresses unmet medical needs and advances treatments for conditions like Alzheimer’s and multiple sclerosis. - September 13, 2024 - Quine Biologics, Inc.

Microvascular Therapeutics Announce Completion of Phase 2 Study Enrollment for MVT-100

Microvascular Therapeutics (MVT), a pioneering healthcare research and development company, is pleased to announce the completion of enrollment in MVT’s Phase 2 program using its microbubble product, MVT-100, for endocardial border delineation. This study, An Ascending Dose Comparison of... - September 13, 2024 - Microvascular Therapeutics, Inc.

MEDraysintell and NucAdvisor Join Forces to Expand Their Activities in Nuclear Medicine Consulting Services

MEDraysintell and NucAdvisor, an independent nuclear consulting company, subsidiary of Soletanche Freyssinet (VINCI Group), France, today announced the integration of the MEDraysintell business into NucAdvisor, including the brand and copyright assets. NucAdvisor will now assume responsibility for... - September 06, 2024 - MEDraysintell

Huntington Study Group and HD Genetics Collaborate to Better Serve HD Gene Positive Patients

Huntington Study Group and HD Genetics Collaborate to Better Serve HD Gene Positive Patients

The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce a strategic partnership with HD Genetics to assist patients who have tested positive for Huntington’s disease (HD) learn about and enroll in research studies. There remains a... - September 05, 2024 - Huntington Study Group

I Holland Launch Tool Room Layout Service

I Holland, a world leader in tablet tooling design and manufacturing, is thrilled to announce the launch of its new, bespoke tool room design service. - August 31, 2024 - I Holland Ltd.

Right Enroll Introduces Comprehensive Medicare Plan Comparison & Selection Platform

Empowering Users to Make Informed Medicare Choices with Ease Right Enroll is happy to announce the launch of new Medicare Plan Comparison & Selection System which is aimed to help a client to find out how to choose the right Medicare plan according to his or her needs and peculiarities. Being... - August 24, 2024 - Right Enroll

Official CelluCare Product Launch: Don’t Fall for Fake Websites

CelluCare, a leader in natural health supplements, announces the official launch of its newest product - a natural supplement designed to support healthy blood sugar levels. With increasing demand, concerns about counterfeit products being sold online have also risen. CelluCare advises consumers to purchase exclusively from the official website to ensure product authenticity and secure transactions, backed by a 60-day money-back guarantee. - August 21, 2024 - CelluCare

Huntington Study Group Announces New CEO

Huntington Study Group Announces New CEO

The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce that Daniel Claassen, MD, MS, an internationally recognized Huntington’s Disease neurologist and researcher has accepted the role as the organization’s Chief Executive... - August 20, 2024 - Huntington Study Group

VitaMist® Announces Exciting Competition: Win a Year’s Supply of Vitamins for You and a Friend

VitaMist®, a leader in Oral Spray Vitamins and Supplements, is thrilled to announce an exciting new competition offering participants the chance to win a year’s supply of vitamins for both themselves and a friend. - August 16, 2024 - VitaMist

Californians Reject Board of Pharmacy’s Proposed Restrictions on Essential Alternative Medicines

Californians Reject Board of Pharmacy’s Proposed Restrictions on Essential Alternative Medicines

Californians fight back against the Board of Pharmacy's proposed regulations that would severely restrict – and in many cases end – access to widely used sterile compounds like methylcobalamin (vitamin B12), glutathione, and NAD, easily accessible and legal in all 49 other United States. The Stop The BOP movement was formed in response, rallying significant public support to preserve access to these essential treatments. - August 08, 2024 - Stop The BOP

Parvus Therapeutics Announces Leadership Appointments to Support Development from Preclinical Into Clinical

New Positions Enhance Parvus Capability to Execute the Translation of Multiple Drug Candidates into the Clinic. - August 06, 2024 - Parvus Therapeutics U.S., Inc.

Minus K Technology Announces Its Ninth Educational Giveaway of Vibration Isolators to U.S. Colleges and Universities

Minus K Technology announces its Educational Giveaway of Vibrations Isolators to U.S. Colleges and Universities. - August 05, 2024 - Minus K Technology Inc.

Silver Scott Mines, Inc. Signs Letter of Intent to Acquire Innovative, Patented Non-Invasive Brain Treatment Technology

Silver Scott Mines will be acquiring the assets of AddBrain, Inc.’s technology. It has been used to treat Huntington’s Disease, Parkinson’s and Suicidal Depression with excellent results. There are ongoing clinical trials in Canada. - August 02, 2024 - Silver Scott Mines, Inc.

GENINVO, a Leading Provider of Innovations in Life Science Announced the Offering of Its On-Demand Service/Tool: DocQC

GENINVO has been working towards automating healthcare industry and contributing to faster drug discovery. GENINVO target to bring innovations as technologies, to automate the traditional and time-consuming process of Medical Writing. One example being, automating the process of clinical and... - August 02, 2024 - GenInvo, Inc.

New Study Explores Potential Benefits of Biophoton Generators in Alzheimer's Care

New Study Explores Potential Benefits of Biophoton Generators in Alzheimer's Care

Study results shared at Alzheimer's Association International Conference in Philadelphia. - July 30, 2024 - Tesla BioHealing, Inc.

Parvus Therapeutics Has Received Orphan Drug Designation for Primary Biliary Cholangitis and Human Research Ethics Committee Approval to Begin Clinical Testing

Parvus Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PVT201 for the treatment of Primary Biliary Cholangitis (PBC) and PVT201 has obtained Australian Human Research Ethics Committee (HREC) approval to initiate a first-in-human... - July 29, 2024 - Parvus Therapeutics U.S., Inc.

Clinical Studies Highlight the Potential of Tesla BioHealing Biophoton Generator in Improving Mobility for Chronic Stroke Patients

Clinical Studies Highlight the Potential of Tesla BioHealing Biophoton Generator in Improving Mobility for Chronic Stroke Patients

Clinical studies indicate that the Tesla BioHealing® Biophoton Generator may help enhance mobility in patients with chronic stroke conditions. - July 24, 2024 - Tesla BioHealing, Inc.

Leap Years®: Supports Age-Related Cognitive Decline in Dogs and Quality Time Together with Owners Through NAD+ Enrichment

Leap Years®: Supports Age-Related Cognitive Decline in Dogs and Quality Time Together with Owners Through NAD+ Enrichment

Animal Biosciences Announces Peer-Reviewed Publication of a Clinical Trial to Evaluate the Slowing of Age-Related Signs in Dogs. After five years of development, clinical results are published regarding senior dog aging in a rigorous, placebo-controlled trial performed at a North Carolina State University College of Veterinary Medicine. - July 23, 2024 - Leap Years

U.S. Precision Medicine, Inc. Signs MOU to Deploy microNeb’s VIGIL Series Inhaler Technology to Enhance Absorption of Its New Drug Candidate in IND Process

U.S. Precision Medicine, Inc. Signs MOU to Deploy microNeb’s VIGIL Series Inhaler Technology to Enhance Absorption of Its New Drug Candidate in IND Process

U.S. Precision Medicine, Inc. (USPM) has signed a Memorandum of Understanding (MOU) to deploy microNeb's advanced inhaler technology to expedite the uptake of its new cancer drug candidate currently in the Investigational New Drug (IND) process. - July 16, 2024 - microNeb, Inc.

Huntington Study Group Announces Launch of LEAD-HD Observational Study

Huntington Study Group Announces Launch of LEAD-HD Observational Study

The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) today announce the release of their newest Patient Reported Outcomes (PRO) study, LEAD-HD. This observational study was developed collaboratively with the University of Rochester Center for Health +... - July 15, 2024 - Huntington Study Group

Tesla BioHealing, Inc. Achieves ISO 13485 QMS Certification

Tesla BioHealing, Inc. Achieves ISO 13485 QMS Certification

Tesla BioHealing, Inc. manufactures unique wellness devices while using a quality management system recently certified by American Systems Registrar (ASR). - July 01, 2024 - Tesla BioHealing, Inc.

I Holland Launches Tooling Safe Disposal & Recycling Service

I Holland, has launched its new Safe Disposal &Recycling Service. This valuable service is designed to ensure the safe, secure, and environmentally responsible destruction of obsolete or worn-out tooling, enhancing both the integrity and sustainability of pharmaceutical manufacturing. Their... - June 23, 2024 - I Holland Ltd.

VITAMIST® Unveils New Enhanced Website for Premium Vitamin Oral Sprays

VITAMIST®, inventor of vitamin oral sprays, is excited to announce the launch of its newly redesigned website, www.vitamist.com. This significant update underscores VITAMIST's commitment to providing high-quality, science-backed vitamin solutions. - June 13, 2024 - VitaMist

Cayman Chemical Expands Molecular Diagnostic Research Offerings Through Partnership with PCRassays.com

Cayman Chemical, a leading supplier of research tools for the life science community, has widened their portfolio to include molecular-based detection kits through a strategic partnership with PCRassays.com. PCRassays.com offers more than 200 qPCR-based assays for infectious diseases, over 50 of... - June 07, 2024 - Cayman Chemical Company

Jusha International and Dextro Imaging Form Strategic Partnership

Jusha International and Dextro Imaging Form Strategic Partnership

Jusha International Collaborates with Dextro Imaging Specialists, Revolutionizing Radiology with Lower Costs and Enhanced Quality - May 28, 2024 - Dextro

GENINVO Launches Its Latest Offering – DocWrightAI

GENINVO, a leading provider of life science products and business solutions announced the launch of its new, on-demand service: DocWrightAI. GENINVO understands the various challenges in generating clinical documents. The time taken to draft clinical documents with accuracy and compliance has... - May 18, 2024 - GenInvo, Inc.

Snova's Halal Extract Wins Its Third Consecutive Gold at the Monde Selection

Snova's Halal Extract Wins Its Third Consecutive Gold at the Monde Selection

Snova’s Halal Extract has won the gold award for its third consecutive year at the Monde Selection 2024. ・Snova’s Halal Extract is a skincare product manufactured in accordance with Islamic law (Halal). In Islam, certain ingredients and manufacturing processes are prohibited, so... - May 15, 2024 - Snova Co.

Dr. Pompa Explores the Hidden Risks of Root Canals

Dr. Pompa discusses the hidden risks of root canals in his latest health coaching initiative, revealing that often these procedures may carry infections that affect surrounding tissues. Despite meticulous care, root canals inherently possess risks, suggesting that sometimes avoiding the procedure might be safer. This exploration underscores the importance of careful decision-making and consultation in dental health and wellness. - May 10, 2024 - Pompa Program

SeabuckWonders Unveils Functional New Product for Women

SeabuckWonders Unveils Functional New Product for Women

Fem-Omega 7 Makes its Debut as Ultimate Supplement for Female Dryness. - May 08, 2024 - SeabuckWonders

Novugen Launches Pazopanib Tablets, 200mg, in the U.S. Following ANDA Approval by USFDA

Novugen Launches Pazopanib Tablets, 200mg, in the U.S. Following ANDA Approval by USFDA

Novugen has launched Pazopanib tablets, 200mg, in the U.S. after receiving ANDA approval from USFDA on April 23, 2024. This significant milestone demonstrates Novugen's continued growth in the U.S. pharmaceutical market with a complex anticancer drug, the generic equivalent of Votrient, used to treat advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS). - May 07, 2024 - Novugen

Pagari Life Science Corp. Announces the Commercial Launch of Helocaine®, a New Transformative Cold Sore Treatment

Pagari Life Science Corp. Announces the Commercial Launch of Helocaine®, a New Transformative Cold Sore Treatment

Pagari Life Science Corporation is revolutionizing cold sore treatment with the commercial launch of Helocaine®. - May 01, 2024 - Pagari Life Sciences

Revolutionizing Clinical Trials: AnzuBridge Unveils Next-Generation Solutions for Improved Efficacy Evaluations in the Treatment of Rare Disease

Revolutionizing Clinical Trials: AnzuBridge Unveils Next-Generation Solutions for Improved Efficacy Evaluations in the Treatment of Rare Disease

AnzuBridge® updates its CDMS to enhance biotech evaluations with advanced video tools, ensuring precise efficacy recording and compliance. It supports scalable trials and features HIPAA-compliant media capture, ePRO for patient engagement, and sophisticated video review capabilities, all integrated with a Learning Management System for efficient trial management. - April 30, 2024 - Anzu

No More Acetone: Thar Process Develops Clean and Green Process to Create Sterile, Fat-Free Lecithin Powder and GMP Quality Oils for Human Consumption

No More Acetone: Thar Process Develops Clean and Green Process to Create Sterile, Fat-Free Lecithin Powder and GMP Quality Oils for Human Consumption

Thar Process, with 34 years of expertise in supercritical fluid extraction, has developed a sustainable way to produce de-fatted lecithin powder that has less oil and longer shelf-life stability. The new process is semi-continuous and sustainable because it utilizes upcycled CO2 from waste sources instead of using toxic acetone which is the industry standard. - April 26, 2024 - Thar Process, LLC

Revvity’s EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings

Revvity’s EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings

Revvity’s EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits throughout the European Union. This... - April 25, 2024 - ALPCO

Mirror Biologics, Inc. Appoints Elizabeth Czerepak as Chief Financial Officer and VP Corporate Development

Mirror Biologics, Inc. Appoints Elizabeth Czerepak as Chief Financial Officer and VP Corporate Development

Mirror Biologics, Inc., a clinical stage biopharmaceutical company announces the appointment of Elizabeth Adkins Czerepak as Chief Financial Officer (CFO) and Vice President of Corporate Development effective April 15, 2024. Ms. Czerepak has served as CFO of several biotechnology companies over... - April 18, 2024 - Mirror Biologics, Inc.

I Holland Unveils TSAR 2: Advancing Predictive Modelling in Tablet Compression

I Holland proudly announces the development of TSAR 2, an advanced predictive model developed through a collaborative partnership between academia and industry. Building upon the success of the Tabletting Science Anti-Stick Research (TSAR) project, I Holland continues its groundbreaking research... - April 12, 2024 - I Holland Ltd.

Boiron’s New Arnicare® Wellness Kits Offer Holistic Approach to Pain Management

Boiron, world leader in homeopathic medicines, introduces its new Arnicare Wellness Kits as convenient and comprehensive solutions for painsleep and stress relief. The kits are designed to provide individuals with daytime and nighttime options to manage pain with occasional sleeplessness and... - April 11, 2024 - Boiron

Huntington Study Group Launches Project AWARE 2.0 Observational Study

Huntington Study Group Launches Project AWARE 2.0 Observational Study

The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce the launch of Project AWARE 2.0, an observational study developed in collaboration with Roche Products Limited and Genentech to understand and improve Awareness, Willingness, and... - April 10, 2024 - Huntington Study Group

Minus K Congratulates to the Winners of Their 2023/2024 Educational Giveaway

Minus K congratulates the four winners of the Minus K's 2023/2024 Educational Giveaway. Over $75,000 of new passive mechanical hub hertz vibration isolators have been granted to universities and colleges in the U.S. over the last ten years. - April 10, 2024 - Minus K Technology Inc.

FuseBio Presents New Data at AACR: Targeting a Functionally-Selective IL-18 (F-18) to PD-1: A Next Generation Checkpoint Inhibitor with Enhanced Anti-Tumor Activity

FuseBio's unique attenuation mechanism renders IL-18, a functionally selective IL-18, resistant to IL-18BP and 1 million percent less active in circulation and yet still retain nearly full activity when targeted to PD-1+/IL-18R+ cells, the key functional immune cells in tumors. It is designed to retain full activity of PD-1 checkpoint blockade and simultaneously deliver a functionally selective IL-18 (F-18) to preserve and enhance the anti-tumor activity of immune cells. - April 09, 2024 - Fuse Biotherapeutics

Renowned Advocate Lorrinda Gray-Davis to Speak at TRIO's Remember & Rejoice Event

Renowned Advocate Lorrinda Gray-Davis to Speak at TRIO's Remember & Rejoice Event

As a guest speaker, Lorrinda Gray-Davis will share her personal journey of hope, resilience, and gratitude, highlighting the profound impact of organ donation on individuals, families, and communities. "Remember & Rejoice" stands as the single largest gathering of donor families and transplant recipients in the country, providing a sacred space for reflection, remembrance, and rejoicing. - April 06, 2024 - TRIO-Oklahoma

Ngram Expands AI Dataset Offerings with Descriptive Question Answering for Healthcare

Ngram Expands AI Dataset Offerings with Descriptive Question Answering for Healthcare

New open-source medchat-qa-descriptive dataset enables AI models to provide comprehensive answers to complex medical queries. - March 22, 2024 - ngram Inc.

Parvus Announces Collaboration with AbbVie to Develop IBD Therapies Based on the Parvus Navacim Platform Technology

The collaboration will combine AbbVie’s expertise in Immunology with Parvus’ innovative Navacim™ regulatory T cells (Treg) immune tolerization platform technology to develop therapies for Inflammatory Bowel Disease Parvus Therapeutics announced today that it has entered into an... - March 20, 2024 - Parvus Therapeutics U.S., Inc.

AMD Stopper, a New Treatment for Age-Related Macular Degeneration, Seeks Partnerships with Manufacturers in the Healthcare Industry

AMD Stopper, a New Treatment for Age-Related Macular Degeneration, Seeks Partnerships with Manufacturers in the Healthcare Industry

California inventor of oral treatment for Age-Related Macular Degeneration, a common eye disease which affects tens of millions globally, is working tirelessly to bring his formulation to market. - March 20, 2024 - AMD Stopper

ACL Digital and PhoenixAI.tech Partner to Take AI-Driven Drone Technology to New Heights

The strategic partnership enhances ACL Digital’s capabilities with PhoenixAI.tech, focusing on AI drone solutions for UAVs, IoT, and edge computing to revolutionize operations significantly Beyond Visual Line of Sight (BVLOS) missions. - March 16, 2024 - ACL Digital

iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease

iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease

iView Therapeutics Inc., a clinical stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, announces that the U.S. Food and Drug Administration (FDA) cleared iView’s Investigational New Drug (IND) application to for the initiation of a Phase 1/2 clinical... - March 11, 2024 - iView Therapeutics Inc.

Defined Bioscience Introduces Ready-CEPT™: A New Cell Viability Enhancer

Defined Bioscience is pleased to announce the launch of Ready-CEPT™ 1000X, a new product designed to improve stem cell survival, growth, and health during critical processes such as routine passaging, cryopreservation, and freeze-thaw recovery. - March 11, 2024 - Defined Bioscience Inc.

Utech Products Inc. Achieves ISO 9001

Utech Products Inc. Achieves ISO 9001 Certification (Certification Registration No. 961 24 5889), Demonstrating Commitment to Quality and Customer Satisfaction. - March 09, 2024 - Utech Products Inc.

IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024

IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024

IVIEW Therapeutics Inc. announces to present the positive topline result in the Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis in the upcoming 2024 ARVO (The Association for Research in Vision and Ophthalmology) national meeting in Seattle, WA. The Presentation... - February 28, 2024 - iView Therapeutics Inc.

Cayman Chemical Introduces LipidLaunch™, Expands Portfolio of Lipid Nanoparticle Research Tools to Support Advances in RNA Therapies

Cayman Chemical introduces the latest addition to the company’s portfolio of lipid nanoparticle (LNP) research tools for academic, pharma, and biotech researchers worldwide. The LipidLaunch™ product line helps researchers pursue LNPs for the delivery of nucleic acid therapies in untold health applications, ranging from vaccine development to cancer and cell or gene therapies. - February 22, 2024 - Cayman Chemical Company

Press Releases 1 - 50 of 3,150